Quidel Stock News

Quidel Corporation (NASDAQ: QDEL) is the best way for investors to play the pandemic right now, says Oppenheimer's Jared Holz. His bullish call is based on strong demand for COVID tests as Omicron con

Jared Holz, Oppenheimer health care equity strategist, joins 'The Exchange' to discuss the surge in Covid-19 cases and what it means for the health care sector. For access to live and exclusive video

Quidel Corporation (NASDAQ:QDEL) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.14% to the previous days close as strong demand from buyers drove the stock to $161.75. Actively observing the price movement in the last trading, the stock closed the session at $152.39, falling within a range of $150.15 and Understanding Quidel Corporation (NASDAQ: QDEL)s Growth Potential Read More »

The omicron variant is spurring sales of COVID-19 tests.

Ziegler Capital Management LLC bought a new stake in Quidel Co. (NASDAQ:QDEL) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 13,614 shares of the companys stock, valued at approximately $1,922,000. Several other institutional investors and hedge funds have also recently modified their holdings of the company. []

Quidel Corporation (NASDAQ: QDEL) (Quidel), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, has executed a multi-year partnership agreement with the Chicago Blackhawks to sponsor team promotions and community services. In the first year of the partnership agreement, the Blackhawks will work with Quidel to provide QuickVue

Related Stocks: MRNA , BIIB , VRTX , ICLR , TECH , NTRA , NTLA , ALXN , NBIX , QDEL , IONS ,

With Lyme disease being identified in record numbers throughout the country, Quidel releases a series of consumer-friendly infographics to help educate Americans on its characteristics, warning signs, seasonality and areas of prevalence. The infographics can be found at LymeDiseaseAnswers.com . “Lyme disease afflicts nearly 480,000 Americans each year; so people are rightfully concerned about where it is most pervasive, how to avoid getting it, and what to do if you think you may have been bitten by an infected tick,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel Corporation. “These infographics provide the information people are seeking in an easy-to-understand manner, and we encourage anyone who spends any time outdoors to educate themselves on this vitally important topic.” One infographic, for example, displays the early warning signs of Lyme disease—which could include headache, fatigue, a bulls-eye rash and muscle aches—while a second infographic depicts such late-stage symptoms as nerve pain, shortness of breath, brain fog and heart palpitations.

With the omicron variant presenting uncertainties regarding how governments will react, here are some stocks to buy to counter that risk. The post 7 Stocks to Buy to Hedge Against Omicron Variant Risk

Quidel Corporation (NASDAQ:QDEL) price on Friday, December 10, fall -3.19% below its previous days close as a downside momentum from buyers pushed the stocks value to $134.06. A look at the stocks price movement, the close in the last trading session was $138.48, moving within a range at $133.74 and $138.98. The beta value (5-Year Quidel Corporation (QDEL) Has Recovered 22.94% From Its Low: Is This The Beginning Of A Trend? Read More »

Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.

The Rapid Influenza Diagnostic Test (RIDT) research report combines vital data incorporating the competitive landscape, global, regional, and country-specific market size, market growth analysis, market share, recent developments, and market growth in segmentation. Furthermore, the Rapid Influenza Diagnostic Test (RIDT)

Shares of Quidel Co. (NASDAQ:QDEL) gapped up before the market opened on Friday . The stock had previously closed at $131.66, but opened at $140.79. Quidel shares last traded at $146.05, with a volume of 4,532 shares changing hands. Several research analysts recently weighed in on QDEL shares. Raymond James lifted their price target on []

The "Infectious Diseases In Vitro Diagnostics" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global Infectious Diseases In Vitro Diagnostics Industry presents a

Wall Street analysts forecast that Quidel Co. (NASDAQ:QDEL) will post $401.23 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Quidels earnings. The lowest sales estimate is $200.70 million and the highest is $524.62 million. Quidel reported sales of $809.20 million during the same quarter last year, which []